Search Results

Your search for Syed Ali Abutalib, MD; Hamza Hashmi, MD; and David L. Porter, MD matches 2 pages

Showing 1 - 2

By Syed Ali Abutalib, MD; Hamza Hashmi, MD; and David L. Porter, MD / November 25, 2019

Answers to Hematology Expert Review Questions

Question 1 Which of the following statements about cytokine-release syndrome and neurotoxicity after tisagenlecleucel infusion is correct? Correct answer: B. The median time to onset of cytokine-release syndrome is 3 days. Expert Perspective Following tisagenlecleucel infusion, cytokine-release...

hematologic malignancies

immunotherapy

By Syed Ali Abutalib, MD; Hamza Hashmi, MD; and David L. Porter, MD / November 25, 2019

CAR T-Cell Gene Therapy: Toxicities and Management Principles

“Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” —Marie Curie The ASCO Post is pleased to present Hematology ...

Dec

Today In Oncology

Search Results

Your search for Syed Ali Abutalib, MD; Hamza Hashmi, MD; and David L. Porter, MD matches 2 pages

Answers to Hematology Expert Review Questions

CAR T-Cell Gene Therapy: Toxicities and Management Principles

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

MRI First Strategy May Be Safe for Prostate Cancer Detection

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL